{
    "clinical_study": {
        "@rank": "117525", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in\n      combination with erlotinib or cetuximab administered to patients with certain types of\n      cancer."
        }, 
        "brief_title": "Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria include, but are not limited to, the following:\n\n          1. Confirmed diagnosis of certain unresectable or metastatic cancers\n\n          2. Adequate Eastern Cooperative Oncology Group (ECOG) performance status\n\n          3. Adequate hepatic, renal and bone marrow function\n\n          4. Resolution of toxicity from prior therapy to grade less than/ = to 1\n\n        Exclusion Criteria include, but are not limited to, the following:\n\n          1. Active brain metastases\n\n          2. Thromboembolic events < 6 months prior to study\n\n          3. Patients with a recent history (within 5 years) of another malignancy.\n\n          4. Investigational or any antitumor treatment with a maximum of 4 half-lives or\n             administered 30 days prior to the initial administration of REGN1400\n\n          5. Patients who are pregnant or nursing\n\n          6. Prior treatment with ErbB3 inhibitors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727869", 
            "org_study_id": "R1400-ST-1113"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "intervention_name": "REGN1400", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cetuximab", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4.", 
            "measure": "The primary objective of the study is to characterize the safety profile of REGN1400 alone and in combination with erlotinib or cetuximab", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 - Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727869"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Determine a recommended phase 2 dose (RP2D) of REGN1400 in combination with erlotinib or cetuximab", 
            "measure": "Recommended Phase 2 Dose (RP2D)", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 to Day 28"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}